Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Salary Range:CHF122,500.00 - CHF227,500.00 BandLevel 5 Job Description SummaryLI#- Hybrid Location: Basel, Switzerland At Novartis, we are reimagining medicine to improve and extend peoples lives. As a Senior Principal Scientist / Associate Director within Molecular &
Salary Range:CHF169,400.00 - CHF314,600.00 Job Description Summary#LI-Hybrid Internal Title: TA Head, PKS Immunology Location: Basel We are seeking an accomplished and visionary scientific leader to join us as TA Head, PK Sciences (PKS) Immunology. In this
At Roche you can show up as yourself, embraced for the unique qualities you bring. Our culture encourages personal expression, open dialogue, and genuine connections, where you are valued, accepted and respected for who you are,
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Are you highly organised, detail-oriented, and passionate about improving processes through technology? Were looking for a Technical Library Administrator to join a leading global organisation in Basel. About the Role As part of the Technical Library Administration team,
Salary Range: CHF146,300.00 - CHF271,700.00 Job Description Summary #LI-Hybrid Location: Basel, Switzerland or Cambridge, United States (see separate posting) Ready to shape the future of innovation at Novartis? As a Patent Attorney, you will play a
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
# Platform Head, Roche Cell and Organoid Biorepository (RoCOB)Applylocations: Baseltime type: Full timeposted on: Posted Todayjob requisition id: At Roche you can show up as yourself, embraced for the unique qualities you bring. Our culture encourages
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
At Roche you can show up as yourself, embraced for the unique qualities you bring. Our culture encourages personal expression, open dialogue, and genuine connections, where you are valued, accepted and respected for who you are,
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS‑addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Salary Range: CHF169,400.00 - CHF314,600.00 Job Description Summary #LI-Hybrid Internal Title: TA Head, PKS Immunology Location: Basel We are seeking an accomplished and visionary scientific leader to join us as TA Head, PK Sciences (PKS) Immunology.
At Roche you can show up as yourself, embraced for the unique qualities you bring. Our culture encourages personal expression, open dialogue, and genuine connections, where you are valued, accepted and respected for who you are,
# Therapeutic Area Head, PK Sciences – ImmunologyREQ- Jul 28, 2026SwitzerlandAvailable in:English# Summary#LI-Hybrid Internal Title: TA Head, PKS Immunology Location: Basel We are seeking an accomplished and visionary scientific leader to join us as TA Head,
Bei Roche kannst du ganz du selbst sein und wirst für deine einzigartigen Qualitäten geschätzt. Unsere Kultur fördert persönlichen Ausdruck, offenen Dialog und echte Verbindungen. Hier wirst du für das, was du bist, wertgeschätzt, akzeptiert und
Viking (NYSE: VIK) is a global leader in experiential travel with a fleet of more than 100 ships, exploring 21 rivers, five oceans and all seven continents. Designed for curious travelers with interests in science, history,
Viking was founded in 1997 and provides destination-focused voyages on oceans, rivers and lakes around the world. Designed for experienced travelers with interests in science, history, culture and cuisine, Chairman Torstein Hagen often says Viking offers
Viking (NYSE: VIK) is a global leader in experiential travel with a fleet of more than 100 ships, exploring 21 rivers, five oceans and all seven continents. Designed for curious travelers with interests in science, history,
Viking (NYSE: VIK) is a global leader in experiential travel with a fleet of more than 100 ships, exploring 21 rivers, five oceans and all seven continents. Designed for curious travelers with interests in science, history,